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Inhaled (ICS) and oral (OCS) corticosteroids are used widely in asthma; however, the risk of 
osteoporosis and fragility fracture (FF) due to corticosteroids in asthma is not well-established. 
Methods  
We conducted two nested case-control studies using linked data from the Clinical Practice 
Research Datalink (CPRD) and Hospital Episode Statistics (HES) databases. Using an 
asthma cohort, we separately identified patients with osteoporosis or FF and gender-, age-, 
and practice-matched controls. Conditional logistic regression was used to determine the 
association between ICS and OCS exposure, and the risk of osteoporosis or FF. The 
prevalence of patients receiving at least one bisphosphonate was also calculated.  
Results 
There was a dose-response relationship between both cumulative dose and number of 
OCS/ICS prescriptions within the previous year, and risk of osteoporosis or FF. After adjusting 
for confounders, people receiving more OCS prescriptions (9 vs 0) had a 4.50 (95%CI: 3.21-
6.11) and 2.16 (95%CI: 1.56-3.32) increased risk of osteoporosis and FF, respectively. For 
ICS (11 vs 0) the odds ratios were 1.60 (95%CI: 1.22-2.10) and 1.31 (95%CI: 1.02-1.68). The 
cumulative dose had a similar impact, with those receiving more OCS or ICS being at greater 
risk. The prevalence of patients taking 9 OCS and at least one bisphosphonate prescription 
was just 50.6% and 48.4% for osteoporosis and FF, respectively. 
Conclusion 
The findings suggest that exposure to OCS or ICS is an independent risk factors for bone 
health in patients with asthma. Steroid administration at the lowest possible level to maintain 




What is the key question? 
➢ What is the impact of oral and inhaled corticosteroid treatment on osteoporosis and 
fragility fracture risk among people with asthma? 
What is the bottom line? 
➢ Exposure to OCS or ICS is an independent risk factor for bone health in patients with 
asthma. There is a clear dose-response relationship between cumulative dose and 
prescriptions of OCS/ICS, and risk of osteoporosis and fragility fractures. 
Why read on? 
➢ The use of ICS in asthma is likely to increase with the recent change in GINA guidance 
recommending combined long-acting-β2-agonists with ICS at step 1 and the 
prescribing of OCS follows an upward trend. Additionally, current guidelines on asthma 
do not fully cover the management of bone comorbidities and no specific bone 
protection guidance is given. This large study using primary and secondary care data 
provides pragmatic guidance to clinicians by stratifying bone health risk by dose, 





Asthma is one of the most common chronic, non-communicable disease affecting around 334 
million people worldwide.(1) Inhaled and oral corticosteroids play a crucial role in the control 
of airway inflammation in asthma.(2) The Global Initiative for Asthma (GINA) guidelines 
suggest a stepwise approach with low to high-dose ICS alone or in combination with long-
acting-β2-agonists as the first line treatment for patients with moderate to severe asthma, and 
use of OCS for patients experiencing exacerbations or having severe asthma.(3) Both ICS 
and OCS are known to cause well-recognised side effects.(4–7)  
One of the most frequent adverse effects is osteoporosis which can lead to fragility 
fractures.(8–10) FF are associated with substantial increased health care costs, morbidity, 
and mortality.(11,12) Studies investigating the adverse effects of corticosteroids on bone 
health based on change in bone mineral density (BMD) in patients with asthma have 
contradictory findings. Laatikainen et al. did not find statistically significant differences in BMD 
between three groups of patients with asthma (ICS (n=26) vs OCS (n=65) vs non-exposed 
(n=28)).(13) Similarly, a 4-year longitudinal study assessing lumbar spine BMD in people with 
asthma receiving low (n=26) and high (n=9) dose of ICS as well as sporadic (n=26) and 
frequent (n=9) OCS did not reveal any change in BMD (p > .05).(14) This might be a result 
due to small sample size in both studies. In contrast, Wong et al. showed that cumulative dose 
of ICS (median, 876 mg) was negatively associated with BMD (p < 0.05) in young patients 
with asthma.(15) Sivri et al. also found a significantly lower BMD in female patients with 
asthma exposed to regular use of ICS (750 to 1500μg/d for at least 3 months).(16) Few studies 
have quantified the risk between corticosteroids and bone health in patients with asthma, 
mostly examining the effects of OCS.(17–19) However, these studies have been limited by 
their small size and focus on severe asthma. 
Given that the use of ICS in asthma is likely to increase with the recent change in GINA 
guidance recommending combined long-acting-β2-agonists with ICS at step 1 (3) and the 
upward trend in prescribing of OCS,(20) we sought to clarify the link between steroids, 
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osteoporosis and FF in patients with asthma stratifying the risk by dose, number of courses, 








We conducted a population-based nested case-control study utilising the Clinical Practice 
Research Datalink GOLD, a large longitudinal primary care database,(21) linked to the 
Hospital Episode Statistics database.(22) We used the July 2018 dataset which covers more 
than 15.4 million patients from 738 practices across the UK. The percentage of patients is 
approximately 7% of the UK population and they are representative with respect to age, 
gender and ethnicity of the wider UK people. HES is a secondary care database consisting of 
all hospitalisations in England, consequently only 60% of CPRD patients have linked data. 
The study was approved by the Independent Scientific Advisory Group of the CPRD (ISAC 
protocol number 19_041RA).  
 
Cohort definition 
The study population included all adult patients (≥18 years old) with a Read code for asthma 
between 1st April 2004 (activation of Quality and Outcomes Framework score) to 31th 
December 2017, with at least 1 year of data collection prior to the diagnosis of asthma date 
ensuring that only ‘incident’ cases were picked.(23) We included patients classed as 
“acceptable” research quality data and registered to an up-to standard practice according to 
CPRD’s recommendations. 
 
Cases, controls, and outcomes definition 
We conducted two nested case-control studies using CPRD linked HES data, with cases 
defined by the first-recorded diagnosis of 1) osteoporosis and 2) fragility fracture (as separate 
outcomes). The databases were linked using an identifier variable (same in both databases) 
called “patid”, and then we looked for the earliest diagnosis in both databases by using either 
the Read or ICD-10 code, depending on the database. The date of the first diagnosis of 1) 
osteoporosis and 2) fragility fracture served as the index date for the cases. Each case was 
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matched with up to four randomly selected patients from the remaining patients with asthma 
by age (±1 year), gender and practice. We assigned the same index date to controls and 
cases.  
Vertebral, hip, forearm-wrist, and humeral fractures are considered common sites of fragility 
fractures, and are associated with morbidity and mortality.(12,24) A composite of these 
fracture sites was used to define the presence of FF. Any fracture described as an “open 
fracture” was excluded, since this type usually occurs via a high-energy event, and is not 
related to frailty. The code list was reviewed by a clinician to identify appropriate fractures that 
were unlikely to be osteoporotic in nature. 
 
Potential confounders 
For each participant in this study, we retrieved information on the following variables which 
are well-established risk for fracture or thought to have an impact on osteoporosis or fracture 
risk and are also likely to be recorded within the databases: age at the index date; sex, 
including only those clearly classified as male or female; body mass index (BMI) using the 
nearest measurement prior the index date and categorised according to the World Health 
Organization (See Online Supplements); smoking and alcohol status using the nearest 
measurement ever prior to the index date (See Online Supplements); socioeconomic status 
measured by using the patient-level Index of Multiple Deprivation (IMD) 2015 in quintiles, with 
quintile 1 being the least and quintile 5 the most deprived; osteoporosis (only when the 
outcome was FF), any fracture (not those considered as an outcome) or falls prior the index 
date; bisphosphonates, Vitamin D and Calcium supplements the year prior the index date. 
The comorbidities were also summarised using the Charlson comorbidity index score.(25) If 





Corticosteroid use was categorised in a number of ways.  Initially, a 1-year period prior to 
index date was used to identify the exposure status. OCS and ICS use were examined as the 
number of prescriptions filled. It was not possible to categorise the OCS use by type since 
97% of individuals received prednisolone. ICS was grouped according to type as follows: 
beclomethasone dipropionate, budesonide, fluticasone propionate, and ciclesonide. Where 
the type of ICS was changed during the year, we considered the most frequently prescribed. 
We also assessed the OCS and ICS as cumulative dose in milligrams (mg) over the previous 
year. To calculate the cumulative OCS and ICS dose, we used information from tablet strength 
(e.g. 5mg) or the dose of drug delivered with each inhalation (e.g. 0.1mg) and prescribed 
quantity, multiplying the quantity by strength for each prescription, and then all doses per 
patient were summed. We dealt with missing or implausible values using a recognised 
algorithm (See Online Supplements).(26) We additionally looked for the exposure in different 
time periods. Thus, the cumulative dose and number of OCS and ICS prescriptions were 
calculated as a rate per year, identifying prescriptions up to 10 years prior the index date 
(median patients’ record time prior the index date), as well as from the asthma to the index 
date. The reference category for all analyses was no steroid exposure. To account for 
differences in potency of different types of corticosteroids, we converted dosages into 




Descriptive statistics were used to summarise the characteristics of the cases and controls. 
To account for the matched design, we used conditional logistic regression deriving 
unadjusted and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) assessing the 
effect of OCS and ICS exposure on the first osteoporosis and FF diagnosis after the asthma 
date, separately. Firstly, we performed a univariate analysis between the exposure and 
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outcome of interest to establish the unadjusted OR. Our a priori confounders were BMI and 
smoking status. The next step was to fit the conditional logistic regression model including the 
exposure of interest and the a priori confounders. Then we added into the model, one at a 
time, each of the other potential confounding variables, removing this potential confounder 
before adding the next. We examined how the OR of the exposure of interest changed as we 
added each potential confounder. If the inclusion of the confounder changed the effect of the 
exposure of interest by more than 5% then it was an important confounder and should be 
placed in the fully adjusted model. Missing data for BMI and smoking status were assumed as 
missing at random and imputed using chained equations. Ten imputations were generated, 
and the imputed model consisted of all listed confounders, OCS and ICS exposure, and the 
case-control indicator. Missing data for IMD were assigned a new category. The prevalence 
of those receiving at least one bisphosphonate (BP) prescription per steroid prescription 
category after their initiation the year prior to the index dates was also calculated. Sensitivity 
analyses was also conducted restring the samples only to patients with at least one ICS 
prescription the year prior to the index dates as a stricter definition of asthma as well as 
restricting the samples only to individuals not in receipt of OCS within the database records 
examining the relationship between ICS and bone comorbidities eliminating any confounding 





Characteristics of the study populations  
We identified 1,564 patients with asthma and osteoporosis, and 3,313 control subjects as well 
as 2,131 patients with asthma and fractures and 4,421 control subjects from a cohort of 69,074 
people with asthma (Table 1, 2). The vast majority were women and the mean age were 69.4 
years (range, 26-95 years) for osteoporosis and 66.4 years (range, 18-94 years) for fractures. 
Patients with asthma and both osteoporosis and fracture were more likely to smoke, had more 
comorbid illness, and were from a lower social class compared with control subjects. The 
cases were more likely to have a previous diagnosis of fall or fracture and had more 









(N=3313) Unadjusted OR 
(95%CI) n (%) n (%) 
Agea (mean±SD), y    69.4±10.7    68.1±10.4     - 
Sex    
Male    303 (19.4)    619 (18.7)     - 
Female 1,261 (80.6) 2,694 (81.3)     - 
Smoking status    
Never    584 (37.3) 1,438 (43.4)   1.00 
Former    584 (37.3) 1,267 (38.3)   1.17 (1.02-1.35) 
Current    381 (24.4)    574 (17.3)   1.95 (1.62-2.33) 
Missing status      15 (01.0)      34 (1.0)   0.93 (0.37-2.32) 
BMI status    
Underweight (<18.5)      76 (04.9)      48 (01.5)   2.25 (1.50-3.36) 
Normal (18.5 - 24.9)    481 (30.7)    654 (19.7)   1.00 
Overweight (25 - 29.9)    435 (27.8)    990 (29.9)   0.56 (0.47-0.67) 
Obese (≥30)    322 (20.6) 1,099 (33.2)   0.39 (0.32-0.46) 
Missing status    250 (16.0)    522 (15.8)   0.63 (0.51-0.79) 
Alcohol status    
Non-drinker    187 (12.0)    323 (09.8)   1.00 
Ex-drinker    181 (11.6)    402 (12.1)   0.81 (0.62-1.05) 
Current drinker 1,052 (67.3) 2,315 (69.9)   0.85 (0.69-1.04) 
Missing status    144 (9.2)    273 (8.2)   1.02 (0.76-1.37) 
IMD (Social Class)    
1 (least deprived)    295 (18.9)    653 (19.7)   1.00 
2    324 (20.8)    688 (20.8)   1.12 (0.91-1.40) 
3    318 (20.3)    710 (21.4)   1.13 (0.90-1.41) 
4    319 (20.4)    665 (20.1)   1.21 (0.96-1.53) 
5 (most deprived)    306 (19.6)    597 (18.0)   1.36 (1.06-1.74) 
Charlson comorbidity index 
1    717 (45.8) 1,847 (55.8)   1.00 
2    258 (16.5)    523 (15.8)   1.27 (1.06-1.52) 
3    274 (17.5)    447 (13.5)   1.51 (1.25-1.81) 
4    151 (9.7)    250 (7.6)   1.54 (1.21-1.94) 
≥5    164 (10.5)    246 (7.4)   1.62 (1.27-2.06) 
Drug use in the year prior the index date 
Bisphosphonates    851 (54.5)    162 (4.9) 25.11 (19.38-32.53) 
Vitamin D and/or 
Calcium  
   418 (26.8)    243 (7.3)   4.47 (3.69-5.40) 
History of a diagnosis ever prior the index date 
Fall    450 (28.8)     575 (17.4)   1.95 (1.65-2.27) 
Any fracture    478 (31.0)     533 (16.1)   2.38 (1.98-2.68) 
  Abbreviations: BMI, body mass index; IMD, Index of Multiple Deprivation. 
  Percentages have been rounded and might not total 100. 












(N=4421) Unadjusted OR 
(95%CI) n (%) n (%) 
Agea (mean±SD), y 65.1±14.9                  64.0±14.1     - 
Sex    
Male    633 (29.8) 1,215 (27.5)     - 
Female 1,497 (70.2) 3,206 (72.5)     - 
Smoking status    
Never    813 (38.2) 1,870 (42.3)   1.00 
Former    767 (36.0) 1,693 (38.3)   1.04 (0.92-1.18) 
Current    513 (24.0)    806 (18.2)   1.53 (1.32-1.77) 
Missing status      38 (01.8)      52 (01.2)   1.81 (0.94-3.49) 
BMI status    
Underweight (<18.5)      79 (3.7)      62 (1.4)   2.28 (1.57-3.29) 
Normal (18.5 - 24.9)    507 (23.8)    905 (20.5)   1.00 
Overweight (25 - 29.9)    588 (27.6) 1,291 (29.2)   0.80 (0.68-0.93) 
Obese (≥30)    538 (25.2) 1,389 (31.3)   0.72 (0.61-0.84) 
Missing status    419 (19.6)    774 (17.5)   0.95 (0.80-1.13) 
Alcohol status    
Non-drinker    203 (09.5)    396 (09.0)   1.00 
Ex-drinker    211 (09.9)    467 (10.6)   0.91 (0.72-1.17) 
Current drinker 1,506 (70.7) 3,156 (71.4)   0.99 (0.82-1.20) 
Missing status    211 (9.9)    402 (9.1)   1.07 (0.82-1.38) 
IMD (Social Class)    
1 (least deprived)    382 (18.0)    893 (20.2)   1.00 
2    468 (22.0)    916 (20.8)   1.25 (1.04-1.50) 
3    442 (20.8)    952 (21.5)   1.16 (0.95-1.40) 
4    418 (19.7)    819 (18.5)   1.26 (1.04-1.55) 
5 (most deprived)    420 (19.7)    840 (19.0)   1.23 (1.04-1.52) 
Charlson comorbidity index 
1 1,195 (56.1) 2,786 (63.0)  1.00 
2    319 (15.0)    643 (14.5)  1.17 (0.99-1.38) 
3    256 (12.0)    460 (10.4)  1.33 (1.11-1.59) 
4    157 (7.4)    268 (6.1)  1.39 (1.11-1.75) 
≥5    204 (9.6)    264 (6.0)  1.71 (1.37-2.13) 
Drug use in the year prior the index date 
Bisphosphonates    255 (12.0)    217 (4.9)   2.57 (2.10-3.15) 
Vitamin D and/or 
Calcium  
   194 (9.1)    260 (5.9)   1.54 (1.25-1.91) 
History of a diagnosis ever prior the index date 
Fall    577 (27.1)     607 (13.7)   2.44 (2.11-2.81) 
Osteoporosis    261 (12.3)     202 (4.6)   2.82 (2.29-3.46) 
Any fracture    707 (33.2)     662 (15.0)   2.94 (2.57-3.36) 
  Abbreviations: BMI, body mass index; IMD, Index of Multiple Deprivation. 
  Percentages have been rounded and might not total 100. 




Corticosteroids and risk of osteoporosis 
A dose-response relationship was observed between the number of prescriptions and 
cumulative dose the year prior and risk of osteoporosis. Two to three OCS prescriptions were 
linked with larger odds of osteoporosis, with those receiving more OCS prescriptions (9 vs 0 
prescriptions; aOR=4.50, 95%CI: 3.21-6.11) and cumulative doses (2500 vs 0 mg; 
aOR=4.79, 95%CI: 3.38-6.79) being at greater risk (Table 3).  
ICS exposure was associated with osteoporosis, but the effect was less strong than with OCS. 
Patients prescribed eleven or more prescriptions were 1.6 times more likely to be diagnosed 
with osteoporosis than controls (aOR=1.60, 95%CI: 1.22-2.10), after adjusting for 
confounders. However, the risk was slightly increased with cumulative doses more than 
120mg the year prior the index date (120 vs 0 mg; aOR=1.63, 95%CI: 1.33-1.99). The risk 
was similar across ICS type, but budesonide had the strongest effect (aOR=1.56, 95%CI: 1.23-




Table 3. Association between Oral (OCS) / Inhaled (ICS) Corticosteroids Exposure in the Year prior to the Index 
Date and Risk of Osteoporosis. 
Type of exposure 
Cases  Controls  Unadjusted OR 
(95%CI) 
Adjusteda OR 
(95%CI) p-value* n % n % 
No OCS use (reference)      992 63.4 2,607 78.8 1.00 1.00 
     
OCS prescriptions           <.0001 
1    188 12.0    371 11.1 1.44 (1.19-1.77) 1.12 (0.90-1.40)    
2-3    123   7.9    189   5.7 1.88 (1.45-2.42) 1.34 (1.12-1.66)    
4-8    161 10.3      98   3.0 4.74 (3.58-6.28) 3.80 (2.81-5.13)  
≥9    100   6.4      48       1.5 5.37 (3.69-7.82) 4.50 (3.21-6.11)  
       
OCS cumulative dose (mg)       <.0001 
≤500    244  15.6    475 14.4 1.47 (1.23-1.77) 1.21 (1.03-1.43)  
501-1000      83    5.3      99   3.0 2.44 (1.75-3.41) 2.05 (1.57-2.68)  
1001-2500    148    9.5      86   2.6 4.77 (3.59-6.40) 4.04 (3.12-5.12)  
>2500      95    6.1      44   1.3 6.10 (4.15-8.98) 4.79 (3.38-6.79)  
        
No ICS use (reference)    569 36.4 1,742 52.6 1.00 1.00 
       
ICS prescriptions            <.0001 
1-6    605 38.7 1,053 31.2 1.87 (1.61-2.17) 1.35 (1.14-1.59)     
7-10    220 14.1    294   8.9 2.49 (2.01-3.07) 1.51 (1.20-1.92)     
≥11    170 10.9    224   6.8 2.66 (2.08-3.39) 1.60 (1.22-2.10)  
      
ICS type                                    
Beclomethasone    423 27.1    783 23.6 1.75 (1.49-2.06) 1.29 (1.08-1.54)   .007** 
Budesonide    207 13.2    300 09.1 2.27 (1.82-2.83) 1.56 (1.23-1.98) <.0001** 
Fluticasone    352 22.5    475 14.3 2.44 (2.04-2.96) 1.44 (1.18-1.77) <.0001** 
Ciclesonide      12   0.9      12   0.5 2.55 (1.13-5.75) 1.80 (0.76-4.27)   .179** 
        
ICS cumulative dose (mg)b       <.0001 
≤40    209 13.4    433 13.1 1.60 (1.37-2.01) 1.18 (0.95-1.47)  
41-80    232 14.8    363 10.1 2.07 (1.62-2.40) 1.26 (0.98-1.60)  
81-120    180 11.5    282 08.5 2.02 (1.74-2.72) 1.50 (1.21-1.87)  
>120    370 23.7    488 14.7 2.55 (2.01-2.97) 1.63 (1.33-1.99)  
a Adjusted for smoking, BMI, IMD, Charlson Comorbidity Index score, any previous fracture, any previous fall, bisphosphonates, 
and number of ICS or OCS prescriptions accordingly. 
b Was not able to determine cumulative dose in 9 individuals.  
Percentages have been rounded and might not total 100. 
*P-values for trend unless otherwise stated. The p-values are referred to the adjusted model. 
** P-values from the Wald’s test   
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Corticosteroids and risk of fragility fracture 
There was an effect of OCS on risk of FF, however the effect size was smaller than on 
osteoporosis. More than nine OCS prescriptions in the previous year had a significant impact 
on risk (9 vs 0 prescriptions; aOR=2.16, 95%CI: 1.56-3.38), whereas OCS cumulative doses 
at more than 1000 mg led to an increased risk in the previous year, with the risk to be greater 
at higher doses in comparison to controls (2500 vs 0 mg; aOR=1.99, 95%CI: 1.30-3.04) 
(Table 4). 
Eleven or more ICS prescriptions were associated with an increased risk of fracture (11 vs 0 
prescriptions; aOR=1.31, 95%CI: 1.02-1.68) (Table 4).  Patients exposed to cumulative doses 
at more than 120 mg in the year prior to the FF were 1.2 times more likely to sustain FF 
(aOR=1.20, 95%CI: 1.08-1.42). No significant association between any ICS type and fragility 
fracture was found. 
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Table 4. Association between Oral (OCS) / Inhaled (ICS) Exposure in the year prior to the Index Date and Risk of 
Fragility Fracture. 
Type of exposure 
Cases  Controls  Unadjusted OR 
(95%CI) 
Adjusteda OR 
(95%CI) p-value* n % n % 
No OCS use (reference) 1,663 78.0 3,676 83.1 1.00 1.00 
      
OCS prescriptions          .0002 
1    219 10.3    410   9.3 1.23 (1.03-1.48) 1.11 (0.91-1.34)    
2-3    112   5.3    171   3.9 1.43 (1.10-1.85) 1.24 (0.95-1.62)    
4-8      85   4.0    123   2.8 1.56 (1.16-2.10) 1.31 (1.12-1.77)    
≥9      52   2.4      41   1.0 2.70 (1.75-4.17) 2.16 (1.56-3.38)  
       
OCS cumulative dose (mg)       .0001 
≤500    279 13.1    507 11.5 1.25 (1.06-1.48) 1.11 (0.92-1.32)  
501-1000      60   2.8      98   2.2 1.39 (0.98-1.96) 1.20 (0.84-1.70)  
1001-2500      79   3.7      93   2.1 1.84 (1.33-2.55) 1.54 (1.10-2.14)  
>2500      50   2.4      47   1.1 2.36 (1.56-3.59) 1.99 (1.30-3.04)  
        
No ICS use (reference)  1,081 50.7 2,527 57.1 1.00 1.00 
      
ICS prescriptions          .010 
1-6    678 31.8 1,330 30.1 1.19 (1.05-1.35) 1.02 (0.89-1.17)  
7-10    219 10.3    340   7.7 1.51 (1.24-1.84) 1.24 (1.01-1.53)  
≥11    153   7.2    224   5.1 1.66 (1.30-2.11) 1.31 (1.02-1.68)  
      
ICS type             
Beclomethasone    510 23.9    984 22.3 1.21 (1.06-1.40) 1.10 (0.94-1.28) .213** 
Budesonide    176 08.3    333   7.5 1.29 (1.04-1.59) 1.14 (0.90-1.44) .269** 
Fluticasone    341 16.0    548 12.4 1.38 (1.16-1.63) 1.04 (0.85-1.26) .679** 
Ciclesonide      16   0.8      24   0.5 2.21 (1.09-4.48) 1.75 (0.82-3.75) .145** 
        
ICS cumulative dose (mg)b       .021 
≤40    257 12.1    560 12.7 1.06 (0.89-1.26) 0.94 (0.78-1.31)  
41-80    248 11.6    433   9.8 1.35 (1.12-1.62) 1.13 (0.93-1.63)  
81-120    194   9.1    332   7.5 1.35 (1.10-1.65) 1.14 (0.90-1.78)  
>120    348 16.3    564 12.8 1.47 (1.25-1.74) 1.20 (1.08-1.42)  
a Adjusted for smoking, BMI, social class, Charlson Comorbidity Index score, any previous fracture, any previous fall, 
bisphosphonates, and number of ICS or OCS prescriptions accordingly.  
b Was not able to determine cumulative dose in 29 individuals. 
Percentages have been rounded and might not total 100. 
*P-values for trend unless otherwise stated. The p-values are referred to the adjusted model. 




The odds ratios in different period analyses were similar to those found when a 1-year period 
prior to index date was used to identify the exposure status. (Supplementary Tables E2-E5). 
 
Sensitivity analysis 
When only patients with at least one ICS prescription before the index dates were included, 
the risk of both osteoporosis and fragility fractures were similar compared to the main analysis 
(Supplementary Tables E6 & E8). After including the patients who never had OCS exposure 
within the database records, the relationship between ICS, osteoporosis, and FF still held 
(Supplementary Tables E7 & E9). 
 
Bisphosphonate use 
The prevalence of OCS users receiving at least one bisphosphonate prescription was 31.4% 
and 21.4% for osteoporosis and FF, respectively (Table 5). When ICS users without an OCS 
prescription in the year prior to the index date were included, the percentage of patients 
receiving at least one bisphosphonate prescription decreased further by around 2%. Only 





Table 5. Prevalence of patients using at least one bisphosphonate prescription after the OCS and ICS initiation in the Year prior to the Osteoporosis and Fragility Fractures 
Diagnosis. 
 Osteoporosis  Fragility Fractures  
Patients with 




category Prevalence  
Patients with 




category Prevalence  
         n n %  n     n % 
OCS prescriptions    
Overall 401  1,275 31.4           259      1,208  21.4 
1 108     559 19.3   92         629  14.6 
2-3   99     309 31.7   50         283  17.6 
4-8 119     259 45.9   72         208  35.5 
≥9   75     148 50.6   45           93  48.4 
ICS prescription     
Overall 868  2,566 33.8 573      2,944  19.4 
1-6 532  1,658 32.0 348      2,008  17.3 
7-10 191     514 37.1 120         559  21.4 
≥11 145     394 36.8 105         377  27.8 
ICS prescription*     
Overall 467  1,579 29.5 314      1,685  18.6 
1-6 314  1,100 28.5 203      1,434  14.2 
7-10   90     280 32.1   63         348  18.1 
≥11   63     199 31.6   48         217  22.1 
                                       BP, Bisphosphonate; ICS, Inhaled Corticosteroids; OCS, Oral Corticosteroid. 





Our findings provide evidence that both OCS and ICS exposure have deleterious effects on 
bone health. We found a clear dose-response relationship, with higher cumulative doses and 
number of OCS and ICS prescriptions being associated with increased odds of osteoporosis 
and fragility fracture. The percentage of patients receiving bisphosphonates after OCS 
initiation was low. 
Our findings are similar to the limited literature. Bloechliger et al. reported a significant dose-
response association between first episode of a bone-related condition and cumulative OCS 
dose in patients with asthma using a nested case-control design, but they did not report the 
odds for osteoporosis and fractures separately.(27) Similarly, a cross-sectional study found 
that OCS were associated with an increased OR for osteoporosis (OR=6.55; 95%CI 4.64-
9.21) and fractures (OR=1.65; 95%CI 1.14-2.39) when comparing patients with severe asthma 
requiring regular OCS treatment with non-asthma controls.(18) Our study adds more details 
by defining the exposure based on the number of prescriptions and cumulative dose, capturing 
both the short- and long-term users. Cumulative doses more than 1000mg within a year had 
a significant effect. Price et al. examined the risk of osteoporosis and osteoporotic fractures in 
patients with asthma exposed to OCS and found similar estimates for cumulative doses (28). 
Our data are also in line with a study reporting that the odds of developing bone and muscle-
related complications increased significantly in a dose-dependent manner with OCS use (29). 
We also found that the number of prescriptions within a year (i.e. intermittent use rather than 
regular) was associated with adverse bone effects, supporting the view that even short 
courses of OCS are harmful to bone health.(5)   
Although the benefits of ICS in asthma are well-documented,(3) the detrimental effects of ICS 
on bones have been less clearly quantified with the majority of the limited literature to be 
relevant to the general population and not to asthma. A Canadian study of elderly women 
failed to detect a high risk of hip fracture (rate ratio = 0.92; 95% CI, 0.75-1.12).(30) Suissa et 
al. found no increased risk of fracture at recommended doses of ICS, but they reported a rate 
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ratio of fracture equal to 1.61 (95% CI, 1.04-2.50) for ≥ 2000μg of ICS per day,(31) although 
this study included only older people (65 yrs) who were already at a higher risk of fractures. 
Hubbard et al. used CPRD data to reveal a dose-response relationship and increased odds of 
hip fracture of 1.19 (95% CI, 1.10-1.28) when adjusting for annual prescriptions of OCS which 
is similar to the odds ratios found in our study.(32) Another study, comparing ICS users with 
non-users, found increased hazard ratios for fracture ranging from 1.13 to 1.51 depending on 
the fracture site.(33) Our study adds to the literature by providing estimates not only about the 
risk of osteoporosis, which are lacking, but also of fragility fractures, capturing a wide range of 
of severity of asthma, whilst adjusting for important confounders. 
The low percentage of bisphosphonate use after the first OCS prescription in the year prior 
the osteoporosis or FF diagnoses is disappointing as this class of drugs is considered the 
most effective bone protective agent. There is guidance on the prevention of bone loss due to 
OCS in the general population, suggesting BP treatment for adults taking, for more than 3 
months, any dose (34,35) or ≥2.5mg of prednisone daily (36). There is no current 
recommendation for BP therapy among ICS users. We found that only a minor percentage of 
ICS users at high risk had at least one bisphosphonate prescription after the first ICS 
prescription in the year prior to the osteoporosis or FF date.  
Current guidelines on asthma do not cover the management of bone comorbidities in detail. 
Although the British Thoracic Society / Scottish Intercollegiate Guidelines Network and the 
Global Initiative for Asthma guidelines on asthma management cover specific co-morbidities 
including osteoporosis, no specific bone protection guidance is given (2,3) and the asthma 
guideline from the National Institute for Health Care and Excellence does not mention 
osteoporosis at all.(37) Our results suggest that risk and prevention of osteoporosis and FF 
should be addressed explicitly in future guideline updates. 
The main strengths of our study are the large study size and use of linked data. By using linked 
data, we have been able to provide more complete estimates of osteoporosis and fractures 
incidence, capturing not only those recorded in primary care as vertebral fractures or 
osteoporosis often do not come to clinical attention in primary care, and people might not be 
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aware of these conditions (38) before a hospitalisation. Our study reports separately the risk 
stratifying data by dose, number of prescriptions, and type of OCS and ICS providing 
pragmatic guidance to clinicians. The dose-response relationship between ICS, osteoporosis, 
and fractures held, even after excluding each individual with a previous OCS exposure within 
the databse records. The population-based setting means the findings are generalizable to 
the wider population.  
This study has some limitations. Diagnostic misclassification may occur, as we were reliant on 
general practitioners recording these conditions. However, these diagnoses have been 
previously validated in the database demonstrating a positive predictive value around 
90%.(39,40) Because of the nature of our data, we may have included some non-fragility 
fractures, however we acted properly to minimize as much as possible this bias. The dose 
response relationship may need to include number of years on OCS or ICS; however, the 
patients’ medical records do not go back indefinitely. Patients may have been using a drug 
prescribed before the examined index periods; however, this would bias the results towards 
the null hypothesis. Inhalers can be difficult to use correctly, and adherence is unlikely to be 
perfect, leading to lesser intake of actual dose underestimating the relationship between a 
prescribed ICS dose and bone health. Our exposure was defined based on corticosteroid 
prescriptions and not on actual compliance. 
Conclusion 
In summary, both OCS and ICS are associated with an increased risk of osteoporosis and 
fragility fracture in people with asthma. The use of OCS and ICS should be kept to the 
minimum necessary to treat symptoms and should be stepped down if symptoms and 
exacerbations are well-managed. Bisphosphonate co-medication should be considered 
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